Safeguard Scientifics stock (US78437J1007): Myomo appoints Safeguard director to board

Myomo Inc. (MYO) appointed Joseph M. Manko Jr., a director at Safeguard Scientifics, to its board effective May 9, 2026, expanding expertise in med-tech investments.

Myomo Inc., a wearable medical robotics company, appointed Joseph M. (Joe) Manko Jr. to its Board of Directors effective May 9, 2026, as disclosed in an 8-K filing with the SEC. Manko, age 60 and Senior Principal at Horton Capital Management LLC—a significant Myomo shareholder—brings over 25 years of experience in investment banking, private equity, asset management, and corporate strategy. He currently serves as a director and Chairman of Safeguard Scientifics, Inc. and director of KORU Medical Systems, Inc. With this addition, Myomo's board expands to seven directors, according to StockTitan as of May 2026 and Investing.com as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Safeguard Scientifics, Inc.
• Sector/industry: Venture capital and growth-stage investments in technology
• Headquarters/country: United States
• Core markets: Healthtech, enterprise software, AI-enabled technologies
• Key revenue drivers: Realization events from portfolio exits, royalty streams
• Home exchange/listing venue: Nasdaq (SFET)
• Trading currency: USD

Safeguard Scientifics: core business model

Safeguard Scientifics invests in growth-stage companies within healthtech, digital enablement, and enterprise software sectors. The firm provides capital and strategic support to portfolio companies, aiming for value creation through operational growth and eventual exits via acquisitions or public offerings. As a publicly traded venture capital entity listed on Nasdaq under ticker SFET, Safeguard generates revenue primarily from realization events, such as equity sales or royalties from successful portfolio monetizations.

Headquartered in Radnor, Pennsylvania, Safeguard focuses on US-based opportunities with scalable technologies. Its model differentiates from traditional VCs by offering public market liquidity to investors while maintaining a concentrated portfolio of high-conviction bets. Recent board activities, including Joseph M. Manko Jr.'s roles, underscore connections to med-tech firms like Myomo.

Main revenue and product drivers for Safeguard Scientifics

Safeguard's revenue stems from 'exits and royalties'—gains from selling stakes in matured portfolio companies and ongoing royalty agreements post-exit. For instance, past realizations from companies like Caris Life Sciences have delivered significant returns. The firm typically holds 8-12 active investments, with healthtech comprising a core pillar alongside AI and cloud platforms.

Key drivers include successful IPOs, M&A transactions, and licensing deals. As a US-listed entity, Safeguard offers retail investors exposure to private-market-like returns with public market transparency, relevant for those tracking venture outcomes amid rising interest in healthtech innovations.

Industry trends and competitive position

The venture capital sector faces headwinds from higher interest rates but sees tailwinds in AI-healthtech convergence. Safeguard positions itself strongly with a track record of 20+ exits since inception, focusing on later-stage companies reduces risk compared to seed-stage VCs. Competitors include publicly traded peers like Hercules Capital, though Safeguard's equity-only focus appeals to growth-oriented US investors.

Why Safeguard Scientifics matters for US investors

Safeguard provides US retail investors indirect access to vetted healthtech and AI startups without private fund lockups. Its Nasdaq listing ensures daily liquidity, while portfolio ties to firms like Myomo—expanding in neuro-orthopedics—highlight exposure to US healthcare spending growth, projected to hit $6.8 trillion by 2030 per CMS data.

Conclusion

The appointment of Safeguard Scientifics director Joseph M. Manko Jr. to Myomo's board highlights deepening ties between venture investors and med-tech operators. For Safeguard, such interconnections reinforce its role in nurturing high-growth healthtech firms. US investors may monitor portfolio progress amid volatile markets, balancing venture upside with execution risks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.